Skip to main
XGN
XGN logo

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc. has demonstrated a solid operational performance with a trailing 12-month average selling price (ASP) for its tests increasing by 9.2% year-over-year, highlighting the effectiveness of its pricing strategy in a competitive diagnostics market. Additionally, the company has reported a notable revenue increase of 19% year-over-year over the first nine months of the year, driven by a combination of ASP growth and a 16% rise in volume, indicating robust demand for its testing products. Furthermore, Exagen's strategic plans to expand its sales territories and improvements in commercial leadership position the company favorably for sustained growth, supported by a healthy cash balance of $35.7 million as of the latest quarter.

Bears say

Exagen Inc. reported mixed results in its recent financial performance, with a revenue of $17.2 million but a GAAP EPS loss of -$0.21, which was below consensus expectations. The company has undergone significant cost-cutting measures, reducing its workforce by approximately 42 full-time equivalents, which raises concerns about its operational efficiency and sales capability moving forward. Additionally, while Exagen has a backlog of $3.5 million, the revenue recognition is expected to be inconsistent, contributing to a negative outlook on its financial stability and growth potential.

Exagen Inc (XGN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.